ADVANCE showed that Preterax* significantly reduces total mortality by 14% and the risk of cardiovacular death by 18%.
In absolute terms, one death would be avoided for every 79 patients treated with Preterax for five years.
In addition, patients receiving Preterax achieved a significant 14% reduction in total coronary events and a 21% reduction in renal events.
That means that one coronary event would be avoided for every 75 patients treated with Preterax for five years and one renal event would be avoided for every 20 patients treated with Pteterax for five years.
“The results of ADVANCE should have major implications for guidelines, clinical care and public policies“, says co-principal study organizer Professor Stephen MacMahon from The George Institute for Global Health, Sydney, Australia, and he adds “These results represent an important step forward in health care for the millions of people with diabetes worldwide. This treatment reduced the likelihood of dying from the complications of diabetes by almost one-fifth, with virtually no side-effetcs“.
ADVANCE-CCB focuses on a subgroup of patients of the ADVANCE trial, to assess the effects of Perindopril and Indapamide in combination with Calcium Channel Blockers (CCB) in patients with type 2 diabetes mellitus.
Active treatment with the fixed combination of Perindopril and Indapamide significantly reduced the relative risk of death by 28% among patients with CCB.
In addition, there was no detectable increase in adverse events.
ADVANCE-CCB demonstrates that the combination of Perindopril, Indapamide, and CCB brings additional protection against mortality in patients with type 2 diabetes mellitus.
*Perindopril / indapamide combinations are registered under the following trade names: Preterax, BiPreterax, Preterax Forte, Biprel, Noliprel, Noliprel Forte, Prelectal, Prelectal forte, Predonium, Noliprel, Coversyl Plus, Coversyl Comp, Coversum Combi, Armix Comb, Prestarium Combi, Prestarium Plus.